Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cytovac A/S is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which is assigned to PRIEST, JESSICA MARIE. As the busiest examiner for the company, PRIEST, JESSICA MARIE is managing 1 pending action, which accounts for the entire active workload. This prosecution is centralized within 1 distinct examiner and 1 distinct art unit, reflecting a focused technical scope.
The 1 pending office action in Biotechnology & Pharmaceuticals indicates a specific point of engagement with the USPTO. Since there is 1 distinct art unit involved, the company's current application is being reviewed within a single specialized group. The busiest examiner, PRIEST, JESSICA MARIE, holds 1 pending action, matching the total number of pending office actions for the portfolio. This alignment means the company's current outcomes in this technology area are tied to the 1 distinct examiner currently assigned.
Practitioners should note that the 1 distinct examiner and 1 distinct art unit provide a singular channel for the company's current intellectual property efforts. With 1 pending office action, there is no current distribution of work across different examiners or units. This concentration under PRIEST, JESSICA MARIE underscores the importance of this examiner's specific review process for the 1 pending office action currently in the pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573186 | METHOD FOR PREPARATION OF CYTOTOXIC T LYMPHOCYTES WITH BROAD TUMOUR-SPECIFIC REACTIVITY AND CHARACTERISTICS OF EARLY DIFFERENTIATION CELLS | PRIEST, JESSICA MARIE | 1642 | §103§112DP | Non-Final OA | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytovac A/S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jessica Marie Priest has the most, with 1 of Cytovac A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
